Bexson Biomedical

Bexson Biomedical is a preclinical-stage biotech company developing non-opioid small molecule therapeutics, initially focused on subcutaneously delivered ketamine for acute and chronic pain management. Their proprietary SEVALENT formulation technology enables precise dosing and subcutaneous delivery of compounds typically administered intravenously, notably ketamine. The company is also exploring applications in mental health, addiction, and multiple psychedelic compounds. Their lead program, BB106, is in development with a wearable, programmable subcutaneous pump co-developed with Stevanato Group, aiming to bring hospital-grade pain and depression management to home and military settings[3][7][11].